Budgetary impact of treating acute bipolar mania in hospitalized patients with quetiapine: An economic analysis of clinical trials

Current Medical Research and Opinion

Volumn 22, Issue 11, 2006, Pages 2233-2242

  Caro, J Jaime ^a,b   Huybrechts, Krista F ^a   Xenakis, James G ^a   O'Brien, Judith A ^a   Rajagopalan, Krithika ^c   Lee, Karen ^a  

^a CARO RESEARCH INSTITUTE   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c ASTRAZENECA   (United Kingdom)

Author keywords

Bipolar disorder; Economic model; Health care costs; Mania; Pharmacoeconomics; Treatment outcome

Indexed keywords

LITHIUM; OLANZAPINE; QUETIAPINE; RISPERIDONE; VALPROATE SEMISODIUM;

AKATHISIA; BIPOLAR DEPRESSION; BIPOLAR MANIA; CONFERENCE PAPER; CONSTIPATION; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DIARRHEA; EXTRAPYRAMIDAL SYNDROME; FEMALE; HEALTH CARE COST; HEALTH CARE SYSTEM; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; NAUSEA; OUTCOME ASSESSMENT; POLYPHARMACY; RATING SCALE; SENSITIVITY ANALYSIS; SIDE EFFECT; SUICIDE ATTEMPT; THEORETICAL MODEL; TREATMENT OUTCOME; VOMITING; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; BUDGETS; CLINICAL TRIALS; DIBENZOTHIAZEPINES; DRUG COSTS; ECONOMICS, PHARMACEUTICAL; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; LENGTH OF STAY; MODELS, ECONOMIC; TREATMENT OUTCOME; UNITED STATES;

EID: 33751218545     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X148265     Document Type: Conference Paper

References (39)

1. Maj M, Akiskal HS, Lopez-Ibor JJ, Sartorius N, editors. Bipolar disorder. West Sussex: John Wiley & Sons, Ltd.; 2002
2. Department of Health and Human Services. Epidemiology of mental illness in mental health: a report of the Surgeon General. Available at: http://www.surgeongeneral.gov/Library/ MentalHealth/chapter2/sec2_1.html
3. MacQueen GM, Young LT, Joffe RT. A review of psychosocial outcome in patients with bipolar disorder. Acta Psychiatr Scand 2001;103:163-70
4. Schatzberg AF. Employing pharmacologic treatment of bipolar disorder to greatest effect. J Clin Psychiatry 2004;65:15-20
5. Sachs G, Chengappa KN, Suppes T, et al. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2004;6:213-23
6. Yatham LN, Paulsson B, Mullen J, Vagero AM. Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania. J Clin Psychopharmacol 2004;24:599-606
7. McIntyre RS, Brecher M, Paulsson B, et al. Quetiapine or haloperidol as monotherapy for bipolar mania - a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol 2005;15:573-85
8. Bowden CL, Grunze H, Mullen J, et al. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry 2005;66:111-21
9. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978;133:429-35
10. Banks J, Carson JS, Nelson BL. Discrete-event system simulation. Englewood Cliffs: Prentice-Hall; 1996
11. Caro JJ. Pharmacoeconomic analysis using discrete event simulation. Pharmacoeconomics 2005;23:323-32
12. Poolsup N, Li Wan Po A, Oyebode F. Measuring mania and critical appraisal of rating scales. J Clin Pharm Ther 1999;24:433-43
13. Pope M, Scott J. Do clinicians understand why individuals stop taking lithium? J Affect Disord 2003;74:287-91
14. Sachs GS, Grossman F, Ghaemi SN, et al. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry 2002;159:1146-54
15. Tohen M, Chengappa KNR, Suppes T, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry 2002;59:62-9
16. Seroquel package insert. Physician's desk reference, 2002
17. Zyprexa package insert. Physician's desk reference, 2002
18. Risperdal package insert. Physician's desk reference, 2002
19. Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania. A double-blind, placebo controlled study. Arch Gen Psychiatry 2000;57:841-9
20. Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. J Am Med Assoc 1994;271:918-24
21. VanPutten T. Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 1974;31:67-72
22. Dalton EJ, Cate-Carter TD, Mundo E, et al. Suicide risk in bipolar patients: the role of co-morbid substance use disorders. J Clin Psychiatry 1999;60:63-9
23. American Association of Suicidology. 2000 official final statistics. Available at: http://www.iusb.edu/~jmcintos/SuicideSTATS/ html
24. Centers for Disease Control. National vital statistics reports. United States Life Table 2000. p. 51 December 19, 2002
25. Oquendo M, Waternaux C, Brodsky B, et al. Suicidal behavior in bipolar mood disorder: clinical characteristics of attempters and nonattempters. J Affect Disord 2000;59:107-17
26. US Bureau of Labor Statistics. Available at: http://www.bls. gov/cpi/
27. Massachusetts Office of Health Care Finance and Policy. 1998 cost-to-charge ratio for Massachusetts hospitals. Boston (MA): Office of Health Care Finance and Policy; 1999
28. Anon. St. Anthony's ICD-9-CM code book. Reston (VA): St. Anthony's Publishing; 1999
29. American Medical Association. Physicians' current procedural terminology. Chicago: American Medical Association; 2002
30. Annual physician fee schedule payment amount file. Centers for Medicare & Medicaid Services, 2002. Available at www.hcfa. gov/stats/pufiles.htm
31. Drug Topics® Redbook®. Montvale (NJ): Thompson Medical Economics; 2004
32. Simons WR, Krishnan AA. The economic value of lamotrigine as a mood stabilizer: a U.S. managed care perspective. Manag Care Interface 2004;17:44-9
33. Gianfrancesco F, Pesa J, Wang RH. Comparison of mental health resources used by patients with bipolar disorder treated with risperidone, olanzapine, or quetiapine. J Manag Care Pharm 2005;11:220-30
34. Namjoshi MA, Rajamannar G, Jacobs T, et al. Economic, clinical, and quality-of-life outcomes associated with olanzapine treatment in mania. Results from a randomized controlled trial. J Affect Disord 2002;69:109-18
35. Zhu B, Tunis SL, Zhao Z, et al. Service utilization and costs of olanzapine versus divalproex treatment for acute mania: results from a randomized, 47-week clinical trial. Curr Med Res Opin 2005;21:555-64
36. Keck PE, Nabulsi AA, Taylor JL, et al. A pharmacoeconomic model of divalproex vs. lithium in the acute and prophylactic treatment of bipolar I disorder. J Clin Psychiatry 1996;57:213-22
37. Lieberman JA, Stroup TS, McEvoy JP, et al; for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New Eng J Med 2005;353:1209-23
38. Jaffe A, Levine J. Antipsychotic medication coprescribing in a large state hospital system. Pharmacoepidemiol Drug Saf 2003;12:41-8
39. Strakowski S, DelBello M, Adler C. Comparative efficacy and tolerability of drug treatments for bipolar disorder. CNS Drugs 2001;15:701-18